MEDP

MEDP

USD

Medpace Holdings Inc. Common Stock

$301.565-0.055 (-0.018%)

即時價格

Healthcare
Diagnostics & Research
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$301.620

最高

$301.910

最低

$301.170

交易量

0.31M

公司基本面

市值

8.7B

行業

Diagnostics & Research

國家

United States

交易統計

平均交易量

0.49M

交易所

NMS

貨幣

USD

52週範圍

最低 $250.05當前 $301.565最高 $459.77

相關新聞

Analyst Upgrades

Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $300

Truist Securities analyst Jailendra Singh maintains Medpace Hldgs with a Hold and lowers the price target from $333 to $300.

查看更多
Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $300
Analyst Upgrades

Baird Maintains Neutral on Medpace Hldgs, Lowers Price Target to $313

Baird analyst Eric Coldwell maintains Medpace Hldgs with a Neutral and lowers the price target from $340 to $313.

查看更多
Baird Maintains Neutral on Medpace Hldgs, Lowers Price Target to $313
Analyst Upgrades

William Blair Downgrades Medpace Hldgs to Market Perform

William Blair analyst Max Smock downgrades Medpace Hldgs from Outperform to Market Perform.

查看更多
William Blair Downgrades Medpace Hldgs to Market Perform
BusinessWire

Medpace Holdings, Inc. Reports First Quarter 2025 Results

Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were

查看更多
Medpace Holdings, Inc. Reports First Quarter 2025 Results
Analyst Upgrades

TD Cowen Downgrades Medpace Hldgs to Hold, Lowers Price Target to $328

TD Cowen analyst Charles Rhyee downgrades Medpace Hldgs from Buy to Hold and lowers the price target from $370 to $328.

查看更多
TD Cowen Downgrades Medpace Hldgs to Hold, Lowers Price Target to $328
Analyst Upgrades

Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $333

Truist Securities analyst Jailendra Singh maintains Medpace Hldgs with a Hold and lowers the price target from $347 to $333.

Analyst Upgrades

Mizuho Maintains Outperform on Medpace Hldgs, Lowers Price Target to $355

Mizuho analyst Ann Hynes maintains Medpace Hldgs with a Outperform and lowers the price target from $400 to $355.